541 – 550 of 1823
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Orellanine specifically targets renal clear cell carcinoma
(
- Contribution to journal › Article
-
Mark
Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer : results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation
(
- Contribution to journal › Article
-
Mark
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Estimating glomerular filtration rate (GFR) in children. The average between a cystatin C- and a creatinine-based equation improves estimation of GFR in both children and adults and enables diagnosing Shrunken Pore Syndrome
(
- Contribution to journal › Article
-
Mark
Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population
(
- Contribution to journal › Article
-
Mark
Clinical practice of BOTOX® treatment for overactive bladder syndrome in Sweden : an assessment of resource use and external validity
2017) In Scandinavian Journal of Urology(
- Contribution to journal › Article
-
Mark
[18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer
(
- Contribution to journal › Article
-
Mark
Similar regulatory mechanisms of caveolins and cavins by myocardin family coactivators in arterial and bladder smooth muscle
(
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Bewegungs- und Trainingstherapie : Nutzen in der Behandlung chronisch Nierenkranker
(
- Contribution to journal › Scientific review